This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kulkarni S , Patil DB , Diaz LK , Wiley EL , Morrow M , Khan SA
COX-2 and PPAR gamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ
Bmc Cancer. 2008 Jan;8 :36
AbstractBackground: In women with duct carcinoma in-situ (DCIS) receiving breast conservation therapy (BCT), in-breast recurrences are seen in approximately 10%, but cannot be accurately predicted using clinical and histological criteria. We performed a case-control study to identify protein markers of local recurrence risk in DCIS. Methods: Women treated for DCIS with BCT, who later developed in-breast recurrence (cases) were matched by age and year of treatment to women who remained free of recurrence (controls). Results: A total of 69 women were included in the study, 31 cases and 38 controls. Immunohistochemical evaluation of DCIS tissue arrays was performed for estrogen receptor, progesterone receptor, HER-2/neu, cyclin D1, p53, p21, cycloxygenase-2 (COX-2) and peroxisome proliferator activated receptor. (PPAR.). Two markers were significantly different between cases and controls on univariate analysis: strong COX-2 expression was associated with increased risk of recurrence, with 67% vs. 24% positivity in cases and controls p = 0.006; and nuclear expression of PPAR. was associated with protection from recurrence with 4% vs. 27% positivity in cases and controls, p = 0.024. In a multivariate model which included size, grade, COX-2 and PPAR. positivity, we found COX-2 positivity to be a strong independent risk factor for recurrence (OR 7.90, 95% CI 1.72-36.23)., whereas size and grade were of borderline significance. PPAR. expression continued to demonstrate a protective trend, (OR 0.14, 95% CI 0.06-1.84). Conclusion: Our findings suggest that COX-2 and PPAR. should be investigated further as biologic markers to predict DCIS recurrence, particularly since they are also potential therapeutic targets.
NotesISI Document Delivery No.: 268RP Times Cited: 0 Cited Reference Count: 65 Cited References: ALTUCCI L, 1996, ONCOGENE, V12, P2315 ARUN B, 2004, SEMIN ONCOL S7, V31, P22 BADAWI AF, 2003, INT J CANCER, V103, P84 BARNES N, 2006, BRIT J CANCER, V94, P253 BARNES NLP, 2005, CLIN CANCER RES, V11, P2163 BOLAND GP, 2004, BRIT J CANCER, V90, P423 BRUEGGEMEIER RW, 2006, MINERVA ENDOCRINOL, V31, P13 BURSTEIN HJ, 2003, BREAST CANCER RES TR, V79, P391 CHASLE J, 2003, EUR J CANCER, V39, P1363 CLAUS EB, 2001, EXP MOL PATHOL, V70, P303 COLLINS LC, 2004, BREAST CANCER RES S1, V88, S191 CORNFIELD DB, 2004, CANCER, V100, P2317 COSTA C, 2002, J CLIN PATHOL, V55, P429 CUTULI B, 2002, INT J RADIAT ONCOL, V53, P868 DANNENBERG AJ, 2003, PROG EXP TUMOR RES, V37, P90 DEMETRI GD, 1999, P NATL ACAD SCI USA, V96, P3951 ELLEDGE RM, 1998, BREAST CANCER RES TR, V52, P79 ELSTNER E, 1998, P NATL ACAD SCI USA, V95, P8806 FAJAS L, 2001, J MOL ENDOCRINOL, V27, P1 FISHER B, 1998, J CLIN ONCOL, V16, P441 FRITAH A, 2005, MOL CELL BIOL, V25, P2419 GROMMES C, 2004, LANCET ONCOL, V5, P419 HALF E, 2002, CANCER RES, V62, P1676 HOQUE A, 2002, CANCER EPIDEM BIOMAR, V11, P587 JIANG WG, 2000, PROSTAG LEUKOTR ESS, V62, P119 JIRSTROM K, 2003, BRIT J CANCER, V89, P1920 KALLIONIEMI OP, 2001, HUM MOL GENET, V10, P657 KEYOMARSI K, 1994, CANCER RES, V54, P380 KOEFFLER HP, 2003, CLIN CANCER RES, V9, P1 KULKARNI S, 2001, CLIN CANCER RES, V7, P429 LATTA EK, 2002, MODERN PATHOL, V15, P1318 LEBEAU A, 2003, BREAST CANCER RES TR, V79, P187 LI CI, 2005, CANCER EPIDEM BIOMAR, V14, P1008 LIVASY CA, 2007, HUM PATHOL, V38, P197 MUELLER E, 1998, MOL CELL, V1, P465 MURPHY GJ, 2000, TRENDS PHARMACOL SCI, V21, P469 OCONNOR JK, 2004, INT J RADIAT ONCOL, V58, P1034 PAGE DL, 1994, CANCER LETT, V86, P1 PAPADAKI I, 2005, HISTOPATHOLOGY, V46, P37 PERRONE G, 2005, HISTOPATHOLOGY, V46, P561 PIGNATELLI M, 2001, J CELL SCI, V114, P4117 PROVENZANO E, 2003, EUR J CANCER, V39, P622 RINGBERG A, 2001, EUR J CANCER, V37, P1514 RISTIMAKI A, 2002, CANCER RES, V62, P632 SCHMID BC, 2004, BREAST CANCER RES TR, V84, P247 SCHMITZ KJ, 2006, J CLIN PATHOL SCHREY MP, 1995, BRIT J CANCER, V72, P1412 SINGH B, 2005, INT J ONCOL, V26, P1393 SOLIN LJ, 2001, INT J RADIAT ONCOL, V50, P991 SOLIN LJ, 2005, CANCER, V103, P1137 SPIEGELMAN BM, 1998, DIABETES, V47, P507 SUBBARAMAIAH K, 2002, J BIOL CHEM, V277, P18649 SUZUKI T, 2006, ENDOCR-RELAT CANCER, V13, P233 TAN KB, 2004, HISTOPATHOLOGY, V44, P24 TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044 VANDEVIJVER MJ, 2005, BREAST, V14, P509 VARGAS C, 2005, INT J RADIAT ONCOL, V63, P1514 VARLEY JM, 1987, ONCOGENE, V1, P423 VICINI FA, 2002, J CLIN ONCOL, V20, P2736 WATANABE O, 2003, ANTICANCER RES, V23, P3215 WEAVER DL, 2006, CANCER, V106, P732 WRIGHT C, 1992, BRIT J CANCER, V65, P118 WULFING P, 2003, J CANCER RES CLIN, V129, P375 YANG XR, 2006, DIAGN MOL PATHOL, V15, P157 YOSHIMURA N, 2003, SURG TODAY, V33, P805 Kulkarni, Swati Patil, Deepa B. Diaz, Leslie K. Wiley, Elizabeth L. Morrow, Monica Khan, Seema A. BIOMED CENTRAL LTD; MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND